Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

3.51
-0.0400-1.13%
Post-market: 3.41-0.0999-2.85%19:58 EDT
Volume:602.53K
Turnover:2.10M
Market Cap:52.73M
PE:-0.67
High:3.65
Open:3.56
Low:3.35
Close:3.55
Loading ...

Company Profile

Company Name:
Jasper Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
64
Office Location:
2200 Bridge Pkwy,Suite 102,Redwood City,California,United States
Zip Code:
94065
Fax:
- -
Introduction:
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

Directors

Name
Position
Ronald Martell
President, Chief Executive Officer and Director
Tom Wiggans
Chairperson of the Board
Christian Nolet
Director
Judith Shizuru
Director
Kurt von Emster
Director
Scott Brun
Director
Svetlana Lucas
Director
Vishal Kapoor
Director

Shareholders

Name
Position
Ronald Martell
President, Chief Executive Officer and Director
Jeet Mahal
Chief Operating Officer
Herb Cross
Chief Financial Officer and Corporate Secretary